Olema Pharmaceuticals (OLMA) Share-based Compensation (2020 - 2026)

Olema Pharmaceuticals (OLMA) has reported Share-based Compensation for 7 consecutive years, with $10.1 million the latest figure, recorded in Q1 2026.

• In Q1 2026, Share-based Compensation rose 131.8% year-over-year to $10.1 million; the TTM figure through Mar 2026 stood at $2.9 million (down 70.46% YoY), while the FY2025 annual figure was $32.1 million, changed N/A from the prior year.
• Share-based Compensation rose to $10.1 million in Q1 2026 per OLMA's latest filing, from -$12.4 million in the prior quarter.
• Across five years, Share-based Compensation topped out at $16.9 million in Q4 2023 and bottomed at -$12.4 million in Q4 2025.
• Historically, Share-based Compensation has averaged $3.1 million across 5 years, with a median of $4.2 million in 2025.
• Annual changes were most pronounced in 2023 — Share-based Compensation soared 15011.61% — and 2025, when it sank 2717.23%.
• Olema Pharmaceuticals' Share-based Compensation stood at $112000.0 in 2022, then jumped by 15011.61% to $16.9 million in 2023, then sank by 102.61% to -$441000.0 in 2024, then tumbled by 2717.23% to -$12.4 million in 2025, then soared by 181.68% to $10.1 million in 2026.
• Business Quant data shows OLMA's Share-based Compensation at $10.1 million in Q1 2026, -$12.4 million in Q4 2025, and $4.2 million in Q3 2025.